Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

BetterMe Rx vs HealthSource

Two GLP-1 desks, one scoreboard. We put BetterMe Rx and HealthSource head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 25 · Grade B

BetterMe Rx

Visit BetterMe Rx Full brief →
vs
No. 51 · Grade C

HealthSource

Visit HealthSource Full brief →

The verdict

BetterMe Rx takes this head-to-head.

BetterMe Rx scores 85 to 79 on our six-factor Brief Score — A LegitScript-certified, app-adjacent program with an oral option and mid-market pricing nationwide.

That doesn't make HealthSource a bad call — it's best for readers who want compounded semaglutide or tirzepatide (injection or oral) in all 50 states from $199/mo. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
78
Supply Reliability
85
68
Transparency
86
88
Access Breadth
90
96
Clinical Oversight
86
81
Track Record
80
63
BetterMe RxBrief Score 85 · 79HealthSource

Price, coverage & the tracker

BetterMe RxHealthSource
Brief Score85/100 (B)79/100 (C)
Semaglutide$199/moFrom $199/mo (all doses, compounded)
Tirzepatide$299/moFrom $299/mo (all doses, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

BetterMe Rx: $199 sema / $299 tirz held at the mid-market line; LegitScript-certified.

HealthSource: New to the tracker on 1 August 2026. The published line reads From $199/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.